X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5099) 5099
Publication (710) 710
Book Review (46) 46
Book Chapter (15) 15
Conference Proceeding (9) 9
Magazine Article (4) 4
Dissertation (3) 3
Web Resource (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4159) 4159
imatinib mesylate (4080) 4080
index medicus (2674) 2674
benzamides (2672) 2672
pyrimidines - pharmacology (2528) 2528
piperazines - pharmacology (2350) 2350
oncology (1798) 1798
antineoplastic agents - pharmacology (1653) 1653
animals (1563) 1563
imatinib (1449) 1449
chronic myeloid-leukemia (1239) 1239
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (1234) 1234
protein kinase inhibitors - pharmacology (1202) 1202
chronic myelogenous leukemia (1138) 1138
pyrimidines - therapeutic use (1114) 1114
male (1093) 1093
pharmacology & pharmacy (1050) 1050
female (1044) 1044
piperazines - therapeutic use (1017) 1017
antineoplastic agents - therapeutic use (992) 992
mice (938) 938
cell line, tumor (917) 917
cancer (851) 851
bcr-abl (848) 848
hematology (841) 841
chronic myeloid leukemia (778) 778
apoptosis - drug effects (740) 740
middle aged (730) 730
drug resistance, neoplasm (695) 695
leukemia (691) 691
protein-tyrosine kinases - antagonists & inhibitors (678) 678
apoptosis (670) 670
adult (663) 663
tyrosine kinase (609) 609
hemic and lymphatic diseases (607) 607
leukemia, myelogenous, chronic, bcr-abl positive - pathology (584) 584
tyrosine kinase inhibitor (582) 582
mutation (580) 580
protein kinase inhibitors - therapeutic use (580) 580
leukemia, myelogenous, chronic, bcr-abl positive - genetics (576) 576
aged (557) 557
cell proliferation - drug effects (557) 557
fusion proteins, bcr-abl - genetics (533) 533
k562 cells (506) 506
research (482) 482
fusion proteins, bcr-abl - metabolism (475) 475
cell biology (453) 453
phosphorylation (445) 445
in-vitro (440) 440
benzamides - pharmacology (432) 432
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (432) 432
tyrosine (425) 425
signal transduction - drug effects (421) 421
expression (418) 418
treatment outcome (418) 418
resistance (416) 416
imatinib mesylate - pharmacology (412) 412
dasatinib (411) 411
gastrointestinal stromal tumors (411) 411
biochemistry & molecular biology (397) 397
dose-response relationship, drug (396) 396
antineoplastic agents (394) 394
pyrimidines - administration & dosage (388) 388
c-kit (386) 386
kinases (378) 378
therapy (366) 366
signal transduction (362) 362
mesylate (358) 358
fusion proteins, bcr-abl - antagonists & inhibitors (356) 356
piperazines - administration & dosage (355) 355
antimitotic agents (354) 354
care and treatment (345) 345
enzyme inhibitors - pharmacology (345) 345
philadelphia-chromosome (345) 345
drug therapy (339) 339
analysis (334) 334
neoplasms (334) 334
cml (324) 324
gastrointestinal stromal tumors - drug therapy (322) 322
drug resistance, neoplasm - genetics (320) 320
article (306) 306
tyrosine kinase inhibitors (303) 303
drug resistance (295) 295
proto-oncogene proteins c-kit - genetics (295) 295
activation (290) 290
tumors (289) 289
drug resistance, neoplasm - drug effects (286) 286
proteins (286) 286
pyrimidines - adverse effects (279) 279
cells (278) 278
cell survival - drug effects (276) 276
chemotherapy (273) 273
genetic aspects (271) 271
tumor cells, cultured (271) 271
antineoplastic agents - administration & dosage (269) 269
health aspects (269) 269
proto-oncogene proteins c-kit - metabolism (268) 268
antineoplastic agents - adverse effects (266) 266
blotting, western (266) 266
drug synergism (266) 266
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4939) 4939
Chinese (83) 83
Japanese (28) 28
French (17) 17
Spanish (11) 11
German (10) 10
Italian (6) 6
Polish (5) 5
Hungarian (4) 4
Russian (2) 2
Czech (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS ONE, ISSN 1932-6203, 10/2017, Volume 12, Issue 10, p. e0185704
Journal Article
Nature Medicine, ISSN 1078-8956, 10/2017, Volume 23, Issue 10, pp. 1234 - 1240
Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs)... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, RESEARCH & EXPERIMENTAL | KINASE-ACTIVITY | COMPLETE MOLECULAR REMISSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | DISCONTINUATION | CELL BIOLOGY | BCR | METABOLISM | FATTY-ACID OXIDATION | IMATINIB | SUPPORTING ASPARTATE BIOSYNTHESIS | DIFFERENTIATION | Metabolomics | Up-Regulation | Minocycline - pharmacology | Neoplastic Stem Cells - drug effects | Humans | Minocycline - analogs & derivatives | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Oxidative Phosphorylation - drug effects | Imatinib Mesylate - therapeutic use | Neoplastic Stem Cells - metabolism | Mass Spectrometry | Chromatography, Liquid | Female | Tumor Cells, Cultured | Drug Therapy, Combination | Cell Survival - drug effects | Tumor Stem Cell Assay | Imatinib Mesylate - pharmacology | Mitochondria - metabolism | Mitochondria - drug effects | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Phenformin - pharmacology | Hypoglycemic Agents - pharmacology | Xenograft Model Antitumor Assays | Animals | Protein Kinase Inhibitors - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice, Inbred NOD | Anti-Bacterial Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | In Vitro Techniques | Drug Resistance, Neoplasm - drug effects | Oxidative stress | Care and treatment | Genotype | Development and progression | Genetic aspects | Chronic myeloid leukemia | Health aspects | Phosphorylation | Transformation | Target recognition | Oxidative metabolism | Leukemia | Xenotransplantation | Disease resistance | Oxidation resistance | Mitochondria | Transformed cells | CD38 antigen | Xenografts | Drug therapy | Protein-tyrosine kinase | Chronic illnesses | Tyrosine | CD34 antigen | Imatinib | Cell survival | Myeloid leukemia | Minimal residual disease | Metabolism | Survival | Oxidative phosphorylation | Antibiotics | Stem cells | Tigecycline
Journal Article
Journal Article
Journal Article
International Journal of Nanomedicine, ISSN 1176-9114, 2015, Volume 10, pp. 3163 - 3170
Journal Article
Nature, ISSN 0028-0836, 06/2016, Volume 534, Issue 7607, pp. 341 - 346
Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kinase BCR-ABL. Direct inhibition of... 
CD34(+) CELLS | INHIBITION | MICROARRAY | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | IMATINIB | TUMOR | COMBINATION | CANCER | EXPRESSION | CHRONIC MYELOID-LEUKEMIA | Antigens, CD34 - metabolism | Tumor Suppressor Protein p53 - antagonists & inhibitors | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Transcriptome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Acetamides - pharmacology | Male | Neoplasm Proteins - metabolism | Tumor Suppressor Protein p53 - genetics | DNA-Binding Proteins - metabolism | Imatinib Mesylate - therapeutic use | Acetamides - therapeutic use | Neoplastic Stem Cells - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Imidazolines - therapeutic use | Neoplastic Stem Cells - pathology | Female | Cell Death - drug effects | Hematopoietic Stem Cells - drug effects | Reproducibility of Results | Imatinib Mesylate - pharmacology | Tumor Suppressor Protein p53 - metabolism | Imidazolines - pharmacology | Hematopoietic Stem Cells - metabolism | Tumor Suppressor Protein p53 - deficiency | Proto-Oncogene Proteins c-myc - metabolism | Neoplastic Stem Cells - transplantation | Azepines - therapeutic use | Azepines - pharmacology | Animals | Signal Transduction - drug effects | Cell Differentiation - drug effects | Hematopoietic Stem Cells - cytology | Proto-Oncogene Proteins c-myc - deficiency | Proteomics | Proto-Oncogene Proteins c-myc - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Proto-Oncogene Proteins c-myc - genetics | Fusion Proteins, bcr-abl - metabolism | Molecular targeted therapy | Cancer cells | Stem cells | Development and progression | Genetic aspects | Chronic myeloid leukemia | Tumor proteins | Properties | Health aspects | Methods | Proteins | Transcription factors | Leukemia | Cell cycle | Kinases | Cancer therapies | Apoptosis
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 10/2016, Volume 126, Issue 10, pp. 3961 - 3980
lmatinib-insensitive leukemia stem cells (LSCs) are believed to be responsible for resistance to BCR-ABL tyrosine kinase inhibitors and relapse of chronic... 
PROGENITOR CELLS | MEDICINE, RESEARCH & EXPERIMENTAL | TYROSINE KINASE | SYMMETRIC DIMETHYLATION | PHILADELPHIA-CHROMOSOME | ARGININE METHYLTRANSFERASE | BONE-MARROW | BETA-CATENIN | IMATINIB MESYLATE | CHRONIC MYELOID-LEUKEMIA | ONCOGENE ADDICTION | RNA, Small Interfering - genetics | Cell Proliferation | Neoplastic Stem Cells - drug effects | Humans | Gene Expression Regulation, Neoplastic | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Protein-Arginine N-Methyltransferases - antagonists & inhibitors | Molecular Targeted Therapy | Gene Knockdown Techniques | STAT5 Transcription Factor - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | 1-Naphthylamine - pharmacology | HEK293 Cells | Female | Antineoplastic Agents - pharmacology | Protein-Arginine N-Methyltransferases - genetics | Aminoquinolines - pharmacology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Gene Expression | Cell Survival | Imatinib Mesylate - pharmacology | Mice, Inbred C57BL | Enzyme Induction | Pyrimidines - pharmacology | Mice, SCID | Protein-Arginine N-Methyltransferases - metabolism | 1-Naphthylamine - analogs & derivatives | Xenograft Model Antitumor Assays | Animals | Cell Line, Tumor | Mice, Inbred NOD | Carbazoles - pharmacology | Neoplastic Stem Cells - enzymology | Fusion Proteins, bcr-abl - metabolism | Care and treatment | Methyltransferases | Development and progression | Genetic aspects | Chronic myeloid leukemia | Properties | Gene expression | Health aspects | Cloning | Leukemia | Mortality | Science | Grants | Kinases | Experiments | Proteins | Stem cells | DNA methylation | Epigenetics | Mutation | Deoxyribonucleic acid--DNA | Cancer
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 11/2015, Volume 16, Issue 11, pp. 27191 - 27207
Journal Article